Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Sold by Jane Street Group LLC

Jane Street Group LLC lessened its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 84.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 60,813 shares of the life sciences company’s stock after selling 327,044 shares during the quarter. Jane Street Group LLC owned 0.08% of Integra LifeSciences worth $1,105,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Versor Investments LP acquired a new position in shares of Integra LifeSciences during the third quarter worth about $612,000. BNP Paribas Financial Markets boosted its holdings in Integra LifeSciences by 824.5% in the third quarter. BNP Paribas Financial Markets now owns 111,775 shares of the life sciences company’s stock valued at $2,031,000 after purchasing an additional 99,685 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in Integra LifeSciences during the third quarter worth approximately $960,000. Point72 Europe London LLP lifted its position in shares of Integra LifeSciences by 13.8% during the 2nd quarter. Point72 Europe London LLP now owns 546,035 shares of the life sciences company’s stock worth $15,911,000 after buying an additional 66,400 shares during the last quarter. Finally, Public Sector Pension Investment Board acquired a new position in shares of Integra LifeSciences in the 2nd quarter valued at $4,395,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Integra LifeSciences

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the sale, the executive vice president now owns 56,182 shares of the company’s stock, valued at $1,357,357.12. This represents a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 3.10% of the company’s stock.

Integra LifeSciences Stock Performance

Shares of IART opened at $22.33 on Monday. Integra LifeSciences Holdings Co. has a 1 year low of $16.81 and a 1 year high of $45.42. The stock has a market capitalization of $1.72 billion, a P/E ratio of -248.08, a P/E/G ratio of 0.82 and a beta of 1.15. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The company’s fifty day moving average is $22.80 and its two-hundred day moving average is $23.14.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $380.80 million during the quarter, compared to analysts’ expectations of $375.81 million. During the same period in the prior year, the company posted $0.76 earnings per share. The firm’s revenue for the quarter was down .4% on a year-over-year basis. On average, sell-side analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on IART. Citigroup lifted their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research note on Tuesday, November 5th. BTIG Research raised Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Bank of America reduced their target price on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. Morgan Stanley started coverage on Integra LifeSciences in a research report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 target price for the company. Finally, Truist Financial cut their price target on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, Integra LifeSciences has a consensus rating of “Hold” and an average price target of $23.00.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.